Applied Clinical Trials Online12h
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...
PMLive5d
Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study
The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...
Olema Oncology price target lowered to $25 from $30 at Oppenheimer
Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Olema Oncology (OLMA) to $25 from $30 but keeps an Outperform rating on ...